Trials / Completed
CompletedNCT03199586
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Novita Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Conditions
- Breast Cancer
- Pancreas Cancer
- Prostate Cancer
- Lung Cancer
- Colon Cancer
- Esophagus Cancer
- Liver Cancer
- Ovary Cancer
- Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NP-G2-044 | capsule |
Timeline
- Start date
- 2017-12-21
- Primary completion
- 2020-05-07
- Completion
- 2020-05-07
- First posted
- 2017-06-27
- Last updated
- 2025-07-20
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03199586. Inclusion in this directory is not an endorsement.